TipRanks
Actinium Pharmaceuticals (DE:7AY1)
FRANKFURT:7AY1
Germany Market
7AY1
Actinium Pharmaceuticals
RESEARCH TOOLSreports

Actinium Pharmaceuticals (7AY1) Stock News & Sentiment

2 Followers
Actinium Pharmaceuticals Expands Actimab-A Patents, Manufacturing Capacity
Premium
Company Announcements
Actinium Pharmaceuticals Expands Actimab-A Patents, Manufacturing Capacity
2M ago
8K
ATNM
Actinium Therapeutics: Buy Rating Reiterated on Emerging Clinical Catalysts and In‑House Ac‑225 Scale-Up, Price Target Maintained at $4
Premium
Ratings
Actinium Therapeutics: Buy Rating Reiterated on Emerging Clinical Catalysts and In‑House Ac‑225 Scale-Up, Price Target Maintained at $4
2M ago
ATNM
Actinium Pharmaceuticals Faces Heightened Key-Person Risk as CEO Sandesh Seth Centralizes Critical Leadership Roles
Premium
Company Announcements
Actinium Pharmaceuticals Faces Heightened Key-Person Risk as CEO Sandesh Seth Centralizes Critical Leadership Roles
2M ago
ATNM
Actinium Submits NYSE Compliance Plan to Restore Listing
Premium
Company Announcements
Actinium Submits NYSE Compliance Plan to Restore Listing
4M ago
8K
ATNM
Actinium Pharmaceuticals: Emerging Pan-Tumor Potential of ATNM-400 Supports Buy Rating and Unchanged $4 Price Target
Premium
Ratings
Actinium Pharmaceuticals: Emerging Pan-Tumor Potential of ATNM-400 Supports Buy Rating and Unchanged $4 Price Target
4M ago
ATNM
Actinium Highlights New ATNM-400 Data Amid Listing Pressure
Premium
Company Announcements
Actinium Highlights New ATNM-400 Data Amid Listing Pressure
5M ago
8K
ATNM
Analyst Reiterates Buy on Actinium, Keeps $4 Price Target Amid Advancing Radiotherapy Pipeline and 2026–2027 Catalysts
Premium
Ratings
Analyst Reiterates Buy on Actinium, Keeps $4 Price Target Amid Advancing Radiotherapy Pipeline and 2026–2027 Catalysts
5M ago
ATNM
More DE:7AY1 News >

7AY1 News on the Web

Actinium Pharmaceuticals Expands Actimab-A Patents, Manufacturing Capacity
TipRanks News
Neutral
Actinium Pharmaceuticals Faces Heightened Key-Person Risk as CEO Sandesh Seth Centralizes Critical Leadership Roles
TipRanks News
Bearish
Actinium Submits NYSE Compliance Plan to Restore Listing
TipRanks News
Bearish
Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026
TipRanks News
Bullish
Actinium Pharmaceuticals: Emerging Pan-Tumor Potential of ATNM-400 Supports Buy Rating and Unchanged $4 Price Target
TipRanks News
Bullish
Actinium Highlights New ATNM-400 Data Amid Listing Pressure
TipRanks News
Bearish
Actinium Pharmaceuticals receives two patent allowances from CIPO
TipRanks News
Bullish
Analyst Reiterates Buy on Actinium, Keeps $4 Price Target Amid Advancing Radiotherapy Pipeline and 2026–2027 Catalysts
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:7AY1’s Media Buzz Sentiment?
Currently, no data Available
What is DE:7AY1’s weekly average amount of articles?
In an average week, 0.25 articles about DE:7AY1 are published.
    What is DE:7AY1’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    NTRANatera
    RYTMRhythm Pharmaceuticals
    MIRMMirum Pharmaceuticals
    HAEHaemonetics
    HRMYHarmony Biosciences Holdings
    Showing the stocks with the most bullish news sentiment over the past week